ESR1 and breast cancer: Considering that AhR/ER crosstalk established for estrogen receptor-positive (ER+) cells and that AhR agonist might be used as a cancer therapeutics opens new possibilities to the medical need for therapy for estrogen receptor-negative (ER‒) breast cancers [141].